The FDA Grants Orphan Drug Designation to Oncternal Therapeutics for the Treatment of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
source: pixabay.com

The FDA Grants Orphan Drug Designation to Oncternal Therapeutics for the Treatment of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

  Orphan drug designations are granted by the FDA to drugs and biologics that are developed for the treatment of rare diseases.  According to a recent article in Biospace, Oncternal…

Continue Reading The FDA Grants Orphan Drug Designation to Oncternal Therapeutics for the Treatment of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
Dr. Eunice Wang Discusses Newly Approved Treatments for Acute Myeloid Leukemia
source: pixabay.com

Dr. Eunice Wang Discusses Newly Approved Treatments for Acute Myeloid Leukemia

  Earlier this year, The Leukemia & Lymphoma Society hosted a presentation by Dr. Eunice Wang, Clinical Leukemia Service, Professor of Oncology, Roswell Park Comprehensive Cancer Center. Dr. Wang’s presentation…

Continue Reading Dr. Eunice Wang Discusses Newly Approved Treatments for Acute Myeloid Leukemia
Experimental CAR NK-Cell Therapy Produces Results in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphona
source: pixabay.com

Experimental CAR NK-Cell Therapy Produces Results in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphona

According to a story from Targeted Oncology, a recent phase 1/2a clinical trial of an experimental treatment called TAK-007 produced a clinical response in the majority of patients in the…

Continue Reading Experimental CAR NK-Cell Therapy Produces Results in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphona
Venclyxto® Plus Obinutuzumab Offers Previously Untreated CLL Patients Chemotherapy-Free Treatment
source: pixabay.com

Venclyxto® Plus Obinutuzumab Offers Previously Untreated CLL Patients Chemotherapy-Free Treatment

  A recent press release by the global biopharmaceutical research company, AbbVie, reported a positive opinion by CHMP granted to VENCLYXTO® combined with obinutuzumab to treat chronic lymphocytic leukemia (CLL). A positive opinion by…

Continue Reading Venclyxto® Plus Obinutuzumab Offers Previously Untreated CLL Patients Chemotherapy-Free Treatment

FDA Grants Orphan Drug Designation to Cellectar’s CLR 131 for the Sixth Time

  The biopharmaceutical company Cellectar Biosciences recently announced that the FDA granted its lead phospholipid drug conjugate, CLR 131, Orphan Drug Designation(ODD) for treatment of lymphoplasmacytic lymphoma. ODD is granted by…

Continue Reading FDA Grants Orphan Drug Designation to Cellectar’s CLR 131 for the Sixth Time
IYCMI: CALQUENCE Has Received US FDA Approval to Benefit Adults with CLL
source: pixabay.com

IYCMI: CALQUENCE Has Received US FDA Approval to Benefit Adults with CLL

  A recent article in BioPortfolio carried AstraZeneca’s announcement of the FDA’s approval of CALQUENCE® (acalabrutinib) for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The approval…

Continue Reading IYCMI: CALQUENCE Has Received US FDA Approval to Benefit Adults with CLL
The FDA Approves New Treatment for Chronic Lymphocytic Leukemia Under an International Program
source: pixabay.com

The FDA Approves New Treatment for Chronic Lymphocytic Leukemia Under an International Program

According to a story from PR Newswire, the US Food and Drug Administration (FDA) has recently granted supplemental approval to the drug acalabrutinib (marketed as Calquence) as a treatment for…

Continue Reading The FDA Approves New Treatment for Chronic Lymphocytic Leukemia Under an International Program
Combination Treatment for Chronic Lymphocytic Leukemia to Soon be Covered on the NHS in Scotland
FrankWinkler / Pixabay

Combination Treatment for Chronic Lymphocytic Leukemia to Soon be Covered on the NHS in Scotland

According to a story from Cancer Research UK, a combination treatment featuring the targeted cancer therapy venetoclax (marketed as Venclyxto) and the monoclonal antibody rituximab will soon be covered by…

Continue Reading Combination Treatment for Chronic Lymphocytic Leukemia to Soon be Covered on the NHS in Scotland
Chronic Lymphocytic Leukemia: Patterns of Treatment, Costs, and Adverse Events
1820796 / Pixabay

Chronic Lymphocytic Leukemia: Patterns of Treatment, Costs, and Adverse Events

According to a story from Cancer Therapy Advisor, a recent study published in the journal Cancer Medicine indicated that chronic lymphocytic leukemia (CLL) patients who dealt with adverse events during treatment…

Continue Reading Chronic Lymphocytic Leukemia: Patterns of Treatment, Costs, and Adverse Events

A Look at Progress in Healthcare and a Glimpse into the Future

  The Asco Post recently interviewed Dr. Jean Pierre Bizzari, the Executive Vice President of Celgene, a multinational bioparmaceutical company. The interview covered various aspects of research and development (R&D)…

Continue Reading A Look at Progress in Healthcare and a Glimpse into the Future

New Combination Treatment Gains Approval for Chronic Lymphocytic Leukemia

According to a story from Rare Disease Report, the US Food and Drug Administration (FDA) has announced its approval of a combination therapy from Janssen which consists of ibrutinib plus…

Continue Reading New Combination Treatment Gains Approval for Chronic Lymphocytic Leukemia
Finding New Treatment Combinations for Chronic Lymphocytic Leukemia
frolicsomepl / Pixabay

Finding New Treatment Combinations for Chronic Lymphocytic Leukemia

According to a story from Onclive, combination therapies are likely to play an increasing role in the treatment of chronic lymphocytic leukemia. In this video, leukemia treatment experts discuss the…

Continue Reading Finding New Treatment Combinations for Chronic Lymphocytic Leukemia
Recent Clinical Trials Highlight Potential of Targeted Therapies for Multiple Myeloma and Chronic Lymphocytic Leukemia
crystal710 / Pixabay

Recent Clinical Trials Highlight Potential of Targeted Therapies for Multiple Myeloma and Chronic Lymphocytic Leukemia

According to a story from PR Newswire, the 60th Annual Meeting of the American Society of Hematology has been generating a lot of press lately as many groundbreaking studies, research,…

Continue Reading Recent Clinical Trials Highlight Potential of Targeted Therapies for Multiple Myeloma and Chronic Lymphocytic Leukemia
Early Dose-Escalation Data for Potential Treatment for Chronic Lymphocytic Leukemia Released
jarmoluk / Pixabay

Early Dose-Escalation Data for Potential Treatment for Chronic Lymphocytic Leukemia Released

According to a story from BioPortfolio, the global biopharmaceutical company Celgene Corporation recently announced the release of early data from the dose-escalation portion of a Phase 1/2 clinical trial of lisocabtagene…

Continue Reading Early Dose-Escalation Data for Potential Treatment for Chronic Lymphocytic Leukemia Released

Presentations Demonstrate Promising Advances in Blood Cancers and Blood Disorders

According to a story from PR Newswire, presentations at the 60th annual American Society of Hematology Meeting and Exposition are highlighting the results of four large scale clinical trials that…

Continue Reading Presentations Demonstrate Promising Advances in Blood Cancers and Blood Disorders
Decorated Admiral in the Center of President Trump Spat is Battling a Rare Form of Cancer
Source: Pixabay.com

Decorated Admiral in the Center of President Trump Spat is Battling a Rare Form of Cancer

You might have heard of the recent political situation where President Donald Trump criticized retired Adm. William H. McRaven on a number of issues. We're not going to dig into…

Continue Reading Decorated Admiral in the Center of President Trump Spat is Battling a Rare Form of Cancer
The FDA has Approved a New Cancer Drug Called Copiktra™ (duvelisib)
qimono / Pixabay

The FDA has Approved a New Cancer Drug Called Copiktra™ (duvelisib)

The United States Food and Drug Administration has approved Copiktra™ (duvelisib). The drug is now approved as a treatment for adult patients diagnosed with refractory or relapsed chronic lymphocytic leukaemia…

Continue Reading The FDA has Approved a New Cancer Drug Called Copiktra™ (duvelisib)
A New Drug Combination May Provide an Effective Treatment for Chronic Lymphocytic Leukemia
Source: Pixabay

A New Drug Combination May Provide an Effective Treatment for Chronic Lymphocytic Leukemia

A phase 3 Murano clinical trial has shown that combining the drugs Venclexta (venetoclax) and Rituxan (rituximab) could be an effective treatment for chronic lymphocytic leukaemia, reports Cancer Updates, Research,…

Continue Reading A New Drug Combination May Provide an Effective Treatment for Chronic Lymphocytic Leukemia
Combination Treatment is Dramatically Improving Outcomes for Mantle Cell Lymphoma Patients
source: pixabay.com

Combination Treatment is Dramatically Improving Outcomes for Mantle Cell Lymphoma Patients

According to a story from adc.net.au, an innovative new cancer treatment regimen is responsible for doubling survival rates for patients with certain types of rare, difficult-to-treat blood cancers. This combination…

Continue Reading Combination Treatment is Dramatically Improving Outcomes for Mantle Cell Lymphoma Patients
Close Menu